title: Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.
abstract: OBJECTIVE
  To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Fifty-two patients with PCOS were randomized in two groups: group A (n = 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (n = 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
  
  
  RESULTS
  The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (-4 % [-31 to 35]) in group B when compared to group A (0 % [-11 to 14]) (P = 0.033). The total mFG score decreased significantly from baseline (-35 % [-71 to 10]) in group A when compared to group B (-18 % [-72 to 30]) (P = 0.035). Changes in androgen hormone profile were comparable except DHEA-SO4 (-32 % [-53 to 15] in group B vs. -10 % [-49 to 63] in group A; P = 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
  
  
  CONCLUSIONS
  Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.
authors.affiliation: Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi, Cebeci, 06100, Ankara, Turkey.
authors.forename: Korhan
authors.initials: K
authors.lastname: Kahraman
authors.forename: Yavuz Emre
authors.initials: YE
authors.lastname: Sükür
authors.forename: Cem Somer
authors.initials: CS
authors.lastname: Atabekoğlu
authors.forename: Can
authors.initials: C
authors.lastname: Ateş
authors.forename: Salih
authors.initials: S
authors.lastname: Taşkın
authors.forename: Serife Esra
authors.initials: SE
authors.lastname: Cetinkaya
authors.forename: Harun Egemen
authors.initials: HE
authors.lastname: Tolunay
authors.forename: Batuhan
authors.initials: B
authors.lastname: Ozmen
authors.forename: Murat
authors.initials: M
authors.lastname: Sönmezer
authors.forename: Bülent
authors.initials: B
authors.lastname: Berker
mesh_terms: D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000097:blood; D000736:Androstenes / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D050260:Carbohydrate Metabolism; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D018384:Oxidative Stress; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D014421:Turkey; D049629:Waist-Hip Ratio
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000736:Androstenes; D015415:Biomarkers; D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D008055:Lipids; D000451:Mineralocorticoid Receptor Antagonists; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C035144:drospirenone